ICCM News

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

IceCure Appoints Meir Peleg as Chief Financial Officer

IceCure Reports 2025 Full Year Financial & Operational Results